Jacobs Levy Equity Management, Inc Jounce Therapeutics, Inc. Transaction History

Jacobs Levy Equity Management, Inc

$24.7 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.64 - $1.99 $997 - $3,102	-1,559 Reduced 5.14%	28,791 $31,000
Q3 2022 Nov 15, 2022	SELL	$2.73 - $4.92 $676,169 - $1.22 Million	-247,681 Reduced 89.08%	30,350 $71,000
Q2 2022 Aug 15, 2022	SELL	$2.8 - $7.67 $105,938 - $290,194	-37,835 Reduced 11.98%	278,031 $842,000
Q1 2022 May 16, 2022	BUY	$6.01 - $8.54 $293,492 - $417,042	48,834 Added 18.29%	315,866 $2.15 Million
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $1.9 Million - $2.57 Million	267,032 New	267,032 $2.23 Million
Q3 2021 Nov 15, 2021	SELL	$5.04 - $8.73 $639,359 - $1.11 Million	-126,857 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$6.58 - $10.66 $7,422 - $12,024	-1,128 Reduced 0.88%	126,857 $863,000
Q1 2021 May 17, 2021	BUY	$6.73 - $13.87 $183,338 - $377,846	27,242 Added 27.04%	127,985 $1.31 Million
Q4 2020 Feb 16, 2021	SELL	$6.37 - $10.33 $522,938 - $848,031	-82,094 Reduced 44.9%	100,743 $705,000
Q3 2020 Nov 16, 2020	BUY	$4.58 - $10.95 $9,567 - $22,874	2,089 Added 1.16%	182,837 $1.49 Million
Q2 2020 Aug 17, 2020	BUY	$4.17 - $7.58 $25,015 - $45,472	5,999 Added 3.43%	180,748 $1.25 Million
Q1 2020 May 15, 2020	BUY	$2.91 - $8.7 $110,155 - $329,329	37,854 Added 27.65%	174,749 $830,000
Q4 2019 Feb 14, 2020	BUY	$2.81 - $9.21 $150,978 - $494,844	53,729 Added 64.6%	136,895 $1.2 Million
Q3 2019 Nov 14, 2019	BUY	$3.33 - $4.93 $71,262 - $105,502	21,400 Added 34.65%	83,166 $277,000
Q2 2019 Aug 13, 2019	BUY	$4.3 - $6.73 $198,943 - $311,370	46,266 Added 298.49%	61,766 $306,000
Q1 2019 May 14, 2019	BUY	$3.43 - $6.87 $53,165 - $106,485	15,500 New	15,500 $96,000

Others Institutions Holding JNCE

# of Institutions

Shares Held

720K

Call Options Held

Put Options Held

View Full List

About Jounce Therapeutics, Inc.

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

More about JNCE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Account